Home Featured Page 301

Featured

Latest

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

Psychedelic Policy Briefing: June 11, 2026

NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase...

Beckley Psytech appoints ex-pharma CEO as Chief Operating Officer

Catching Up With the Psychedelic Entourage Effect: Part 5 – MindMed

The Psychedelic Entourage Effect: Part 6 – The State of the...

Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry...

Bright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of...

Researchers to Investigate Whether DMT Can Accelerate Recovery from Stroke

Lobe Sciences Signs Definitive Agreement for Sale of Cowlitz Cannabis Assets...

PT232 – Dr. Ryan Westrum – Who We Are Without Medicine

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

Psychedelic Policy Briefing: June 11, 2026

NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase...

Beckley Psytech appoints ex-pharma CEO as Chief Operating Officer

Catching Up With the Psychedelic Entourage Effect: Part 5 – MindMed

The Psychedelic Entourage Effect: Part 6 – The State of the...

Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry...

Bright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of...

Researchers to Investigate Whether DMT Can Accelerate Recovery from Stroke

DMT Pricing Guide

Lobe Sciences Signs Definitive Agreement for Sale of Cowlitz Cannabis Assets...

PT232 – Dr. Ryan Westrum – Who We Are Without Medicine

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY